by Laura Farmer, Opus Strategy
It’s tempting to read the FDA’s new real-time clinical trial initiative as just another agency modernization effort. But for biopharma sponsors, that would be a mistake.
The early pilots are limited but instructive. AstraZeneca is participating through its Phase 2 TRAVERSE trial evaluating Calquence with venetoclax and rituximab in treatment-naïve mantle cell lymphoma; Amgen through an early-stage study of Imdelltra/tarlatamab, its DLL3-targeted T-cell engager in small cell lung cancer. In both cases, the stated objective is to allow FDA reviewers to access predefined safety and efficacy signals in near real time, rather than waiting for data to be collected, analyzed, and submitted through traditional review cycles.
In other words: real-time review is not a faster version of the current process but a fundamentally different operating model for clinical development. To be ready, sponsors will need to navigate at least three operational shifts.
Data infrastructure comes first. Paradigm Health, which is supporting the AstraZeneca pilot, describes a model that captures data directly from EHRs and other structured and unstructured sources, evaluates FDA-defined data points algorithmically, and transmits only those signals needed for regulatory determinations. That level of integration is not a minor workflow adjustment. It requires interoperable systems, standardized endpoint definitions, site-level data discipline, and auditability strong enough to support regulatory reliance.
Site strategy becomes even more consequential. If real-time review depends on data flowing cleanly from clinical sites into regulator-facing systems, sponsors will need to rethink how they assess trial networks. Traditional measures of site prestige or enrollment potential will still matter, but they may no longer be sufficient. Digital maturity, EHR integration, data quality, and operational responsiveness may become criteria for regulatory readiness.
Cross-functional integration can no longer be deferred. Functions that have traditionally operated in sequence (clinical, regulatory, data science, AI governance) will need to operate in close alignment far earlier in development. The FDA’s related request for information on AI-enabled optimization of early-phase trials specifically identifies safety monitoring, dose selection, and early go/no-go decisions as areas of focus. Sponsors that approach this as an IT project will miss the point. The core challenge is whether an organization can define, validate, and explain the signals regulators want to see.
Still, there are caveats. This remains a pilot, and a narrow one at that. It will not replace formal submissions, and FDA officials have emphasized that the initial focus is on predefined endpoints rather than unrestricted access to patient-level data. The tension between speed and evidentiary rigor has not been resolved. Faster visibility does not automatically produce better decisions.
But the strategic signal is hard to ignore. The FDA is testing whether review can become more continuous and less episodic. For biopharma sponsors, that means regulatory advantage may increasingly depend on development infrastructure, not just clinical data quality.
The companies best positioned to benefit will be those that can answer a few practical questions now:
The last question may be the most important. Real-time review cannot be opted into at the end of a trial – it must be incorporated into the development process from the point of FPI.
At Opus Strategy, we help biopharma teams translate regulatory and technology shifts into practical strategic decisions. Here, the question is not whether every trial will become “real-time.” It is whether sponsors are prepared for a regulatory environment in which continuous evidence generation becomes a competitive advantage.